A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced Thursday. The once-daily pill, called orforglipron, helped patients with Type 2 diabetes lower their drug sugar levels and lose weight during late-stage trials, the drugmaker said. The trial results are being...
Johnson says 4.8 million Americans won't lose Medicaid access 'unless they choose to do so'
- today, 11:22 AM
- thehill.com
- 0
No comments